Published in Clin Cancer Res on August 01, 2008
Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer (2013) 4.46
Decoding melanoma metastasis. Cancers (Basel) (2010) 1.02
p53-Inducible DHRS3 is an endoplasmic reticulum protein associated with lipid droplet accumulation. J Biol Chem (2011) 0.95
Prognostic biomarkers in thyroid cancer. Virchows Arch (2014) 0.95
IRX1 hypomethylation promotes osteosarcoma metastasis via induction of CXCL14/NF-κB signaling. J Clin Invest (2015) 0.95
Chemokine CXCL14 is associated with prognosis in patients with colorectal carcinoma after curative resection. J Transl Med (2013) 0.92
RNA sequencing identifies multiple fusion transcripts, differentially expressed genes, and reduced expression of immune function genes in BRAF (V600E) mutant vs BRAF wild-type papillary thyroid carcinoma. J Clin Endocrinol Metab (2013) 0.86
PVALB, a new Hürthle adenoma diagnostic marker identified through gene expression. J Clin Endocrinol Metab (2010) 0.86
Measurement of calcitonin and calcitonin gene-related peptide mRNA refines the management of patients with medullary thyroid cancer and may replace calcitonin-stimulation tests. Thyroid (2013) 0.80
Fine map of the Gct1 spontaneous ovarian granulosa cell tumor locus. Mamm Genome (2012) 0.79
The Effects of Hashimoto Thyroiditis on Lymph Node Metastases in Unifocal and Multifocal Papillary Thyroid Carcinoma: A Retrospective Chinese Cohort Study. Medicine (Baltimore) (2016) 0.78
Genome-wide expression analysis suggests a crucial role of dysregulation of matrix metalloproteinases pathway in undifferentiated thyroid carcinoma. BMC Genomics (2015) 0.76
BRAFV600E-Associated Gene Expression Profile: Early Changes in the Transcriptome, Based on a Transgenic Mouse Model of Papillary Thyroid Carcinoma. PLoS One (2015) 0.75
The uS8, uS4, eS31, and uL14 Ribosomal Protein Genes Are Dysregulated in Nasopharyngeal Carcinoma Cell Lines. Biomed Res Int (2017) 0.75
Gene expression profiling predicts clinical outcome of breast cancer. Nature (2002) 71.36
A molecular signature of metastasis in primary solid tumors. Nat Genet (2002) 21.36
Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell (2004) 9.41
High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res (2003) 8.67
Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol (2006) 3.48
BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene (2003) 3.34
Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. Proc Natl Acad Sci U S A (2001) 2.38
Retracted The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. J Clin Invest (2005) 2.09
Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. Oncogene (2005) 1.99
Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer. Oncogene (2004) 1.82
Molecular characterization of a novel short-chain dehydrogenase/reductase that reduces all-trans-retinal. J Biol Chem (1998) 1.66
Cloning of BRAK, a novel divergent CXC chemokine preferentially expressed in normal versus malignant cells. Biochem Biophys Res Commun (1999) 1.56
In vivo expression of the novel CXC chemokine BRAK in normal and cancerous human tissue. Am J Pathol (2000) 1.51
A preoperative diagnostic test that distinguishes benign from malignant thyroid carcinoma based on gene expression. J Clin Invest (2004) 1.48
Identification, cloning, and characterization of cystatin M, a novel cysteine proteinase inhibitor, down-regulated in breast cancer. J Biol Chem (1997) 1.19
RET/PTC oncogene activation is an early event in thyroid carcinogenesis. Oncogene (1995) 1.19
retSDR1, a short-chain retinol dehydrogenase/reductase, is retinoic acid-inducible and frequently deleted in human neuroblastoma cell lines. Cancer Res (2002) 1.17
Osteopontin is overexpressed in human papillary thyroid carcinomas and enhances thyroid carcinoma cell invasiveness. J Clin Endocrinol Metab (2005) 1.17
Papillary and follicular thyroid carcinomas show distinctly different microarray expression profiles and can be distinguished by a minimum of five genes. J Clin Oncol (2004) 1.16
The chemokine CXCL14 (BRAK) stimulates activated NK cell migration: implications for the downregulation of CXCL14 in malignancy. Exp Hematol (2006) 1.12
Cystatin m: a novel candidate tumor suppressor gene for breast cancer. Cancer Res (2004) 1.10
DNA methylation-dependent silencing of CST6 in human breast cancer cell lines. Lab Invest (2006) 1.10
Diagnosis of suspicious thyroid nodules using four protein biomarkers. Clin Cancer Res (2006) 1.07
Autocrine stimulation by osteopontin plays a pivotal role in the expression of the mitogenic and invasive phenotype of RET/PTC-transformed thyroid cells. Oncogene (2004) 0.92
Upregulation of cystatin M during the progression of oropharyngeal squamous cell carcinoma from primary tumor to metastasis. Oral Oncol (2003) 0.92
Molecular profiling of matched samples identifies biomarkers of papillary thyroid carcinoma lymph node metastasis. Cancer Res (2007) 0.91
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
An integrated genomic analysis of human glioblastoma multiforme. Science (2008) 51.36
IDH1 and IDH2 mutations in gliomas. N Engl J Med (2009) 32.41
High frequency of mutations of the PIK3CA gene in human cancers. Science (2004) 27.94
Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med (2014) 8.36
The genetic landscape of the childhood cancer medulloblastoma. Science (2010) 8.34
TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A (2013) 6.88
Altered telomeres in tumors with ATRX and DAXX mutations. Science (2011) 4.60
An anatomy of normal and malignant gene expression. Proc Natl Acad Sci U S A (2002) 4.45
Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget (2012) 3.88
PIK3CA gene mutations in pediatric and adult glioblastoma multiforme. Mol Cancer Res (2006) 3.72
Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. Cancer Res (2010) 3.30
Comprehensive sampling of gene expression in human cell lines with massively parallel signature sequencing. Proc Natl Acad Sci U S A (2003) 2.64
Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists. Cancer Cell (2013) 2.62
Optimizing nucleic acid extraction from thyroid fine-needle aspiration cells in stained slides, formalin-fixed/paraffin-embedded tissues, and long-term stored blood samples. Arq Bras Endocrinol Metabol (2012) 2.57
Molecular markers in ductal carcinoma in situ of the breast. Mol Cancer Res (2003) 2.55
Sequence survey of receptor tyrosine kinases reveals mutations in glioblastomas. Proc Natl Acad Sci U S A (2005) 2.38
A mouse atlas of gene expression: large-scale digital gene-expression profiles from precisely defined developing C57BL/6J mouse tissues and cells. Proc Natl Acad Sci U S A (2005) 2.35
Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion. Cancer Res (2002) 2.23
Gastric cancers overexpress S100A calcium-binding proteins. Cancer Res (2002) 1.81
The generation and utilization of a cancer-oriented representation of the human transcriptome by using expressed sequence tags. Proc Natl Acad Sci U S A (2003) 1.79
Genomic amplification of orthodenticle homologue 2 in medulloblastomas. Cancer Res (2005) 1.75
Cigarette, cigar, and pipe smoking and the risk of head and neck cancers: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. Am J Epidemiol (2013) 1.73
Investigation of BRAF mutation in a series of papillary thyroid carcinoma and matched-lymph node metastasis reveals a new mutation in metastasis. Clin Endocrinol (Oxf) (2005) 1.72
A mutation in the KCNE3 potassium channel gene is associated with susceptibility to thyrotoxic hypokalemic periodic paralysis. J Clin Endocrinol Metab (2002) 1.67
Establishment and characterization of a primary human chordoma xenograft model. J Neurosurg (2012) 1.60
A survey of glioblastoma genomic amplifications and deletions. J Neurooncol (2009) 1.52
A preoperative diagnostic test that distinguishes benign from malignant thyroid carcinoma based on gene expression. J Clin Invest (2004) 1.48
Large-scale transcriptome analyses reveal new genetic marker candidates of head, neck, and thyroid cancer. Cancer Res (2005) 1.47
Glycoprotein nonmetastatic melanoma protein B, a potential molecular therapeutic target in patients with glioblastoma multiforme. Clin Cancer Res (2006) 1.41
Abrogation of PIK3CA or PIK3R1 reduces proliferation, migration, and invasion in glioblastoma multiforme cells. Oncotarget (2011) 1.39
Meningioma transcript profiles reveal deregulated Notch signaling pathway. Cancer Res (2005) 1.33
Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine. Oncotarget (2013) 1.31
5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft. Oncotarget (2013) 1.28
Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme. Neuro Oncol (2011) 1.26
Identification of several novel non-p.R132 IDH1 variants in thyroid carcinomas. Eur J Endocrinol (2010) 1.23
The impact of SNPs on the interpretation of SAGE and MPSS experimental data. Nucleic Acids Res (2004) 1.19
Inhibition of Akt inhibits growth of glioblastoma and glioblastoma stem-like cells. Mol Cancer Ther (2009) 1.18
Generation and analysis of melanoma SAGE libraries: SAGE advice on the melanoma transcriptome. Oncogene (2004) 1.18
Exomic sequencing of four rare central nervous system tumor types. Oncotarget (2013) 1.17
Comparison of medulloblastoma and normal neural transcriptomes identifies a restricted set of activated genes. Oncogene (2003) 1.14
Recurrent laryngeal nerve: a plexus rather than a nerve? Arch Otolaryngol Head Neck Surg (2009) 1.14
DDIT3, STT3A (ITM1), ARG2 and FAM129A (Niban, C1orf24) in diagnosing thyroid carcinoma: variables that may affect the performance of this antibody-based test and promise. Mod Pathol (2013) 1.12
The Axl receptor tyrosine kinase is an adverse prognostic factor and a therapeutic target in esophageal adenocarcinoma. Cancer Biol Ther (2010) 1.12
Somatic mutations of GUCY2F, EPHA3, and NTRK3 in human cancers. Hum Mutat (2006) 1.12
[Thyrotoxic hypokalemic periodic paralysis, an endocrine emergency: clinical and genetic features in 25 patients]. Arq Bras Endocrinol Metabol (2004) 1.07
Diagnosis of suspicious thyroid nodules using four protein biomarkers. Clin Cancer Res (2006) 1.07
Oncogenomics and the development of new cancer therapies. Nature (2004) 1.06
Glioblastoma cell growth is suppressed by disruption of Fibroblast Growth Factor pathway signaling. J Neurooncol (2009) 1.04
Identification of astrocytoma associated genes including cell surface markers. BMC Cancer (2004) 1.04
PLXDC1 (TEM7) is identified in a genome-wide expression screen of glioblastoma endothelium. J Neurooncol (2006) 1.02
Re-expression of ABI3-binding protein suppresses thyroid tumor growth by promoting senescence and inhibiting invasion. Endocr Relat Cancer (2008) 1.01
Altered cancer cell metabolism in gliomas with mutant IDH1 or IDH2. Curr Opin Oncol (2012) 1.00
OTX2 represses myogenic and neuronal differentiation in medulloblastoma cells. Cancer Res (2012) 0.98
Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic strategy. Tumour Biol (2013) 0.98
Perineural invasion in aggressive skin carcinomas of the head and neck. Potentially dangerous but frequently overlooked. ORL J Otorhinolaryngol Relat Spec (2008) 0.98
MRP3: a molecular target for human glioblastoma multiforme immunotherapy. BMC Cancer (2010) 0.96
Coexpression of neuronatin splice forms promotes medulloblastoma growth. Neuro Oncol (2008) 0.96
Identification of microbial DNA in human cancer. BMC Med Genomics (2009) 0.95
c-Myc promoter activation in medulloblastoma. Cancer Res (2003) 0.93
Early diagnosis of multiple endocrine neoplasia type 2B: a challenge for physicians. Arq Bras Endocrinol Metabol (2008) 0.93
Splicing factors are differentially expressed in tumors. Genet Mol Res (2004) 0.93
Skip metastases in medullary thyroid carcinoma: a single-center experience. Surg Today (2008) 0.91
Molecular profiling of matched samples identifies biomarkers of papillary thyroid carcinoma lymph node metastasis. Cancer Res (2007) 0.91
Establishment of a human glioblastoma stemlike brainstem rodent tumor model. J Neurosurg Pediatr (2010) 0.91
A robust approach to enhance tumor-selective accumulation of nanoparticles. Oncotarget (2011) 0.91
Ghrelin and the growth hormone secretagogue receptor constitute a novel autocrine pathway in astrocytoma motility. J Biol Chem (2006) 0.91
A novel germ-line point mutation in RET exon 8 (Gly(533)Cys) in a large kindred with familial medullary thyroid carcinoma. J Clin Endocrinol Metab (2003) 0.91
Podocalyxin-like protein is expressed in glioblastoma multiforme stem-like cells and is associated with poor outcome. PLoS One (2013) 0.91
Tumor subtype-specific cancer-testis antigens as potential biomarkers and immunotherapeutic targets for cancers. Cancer Immunol Res (2013) 0.90
Serial analysis of gene expression identifies connective tissue growth factor expression as a prognostic biomarker in gallbladder cancer. Clin Cancer Res (2008) 0.90
Targeting the AKT pathway in glioblastoma. Curr Pharm Des (2011) 0.90
Sodium ion channel mutations in glioblastoma patients correlate with shorter survival. Mol Cancer (2011) 0.89
Evaluation of tyrosine kinase inhibitor combinations for glioblastoma therapy. PLoS One (2012) 0.89
A transcript finishing initiative for closing gaps in the human transcriptome. Genome Res (2004) 0.89
Genomics and proteomics approaches to the study of cancer-stroma interactions. BMC Med Genomics (2010) 0.87
The RET p.G533C mutation confers predisposition to multiple endocrine neoplasia type 2A in a Brazilian kindred and is able to induce a malignant phenotype in vitro and in vivo. Thyroid (2011) 0.87
A novel small molecule that selectively inhibits glioblastoma cells expressing EGFRvIII. Mol Cancer (2007) 0.87
ABI3 ectopic expression reduces in vitro and in vivo cell growth properties while inducing senescence. BMC Cancer (2011) 0.86
Global gene expression profiling of oral cavity cancers suggests molecular heterogeneity within anatomic subsites. BMC Res Notes (2008) 0.86
PVALB, a new Hürthle adenoma diagnostic marker identified through gene expression. J Clin Endocrinol Metab (2010) 0.86
Evaluation of retinoic acid therapy for OTX2-positive medulloblastomas. Neuro Oncol (2010) 0.86
Genetic markers differentiating follicular thyroid carcinoma from benign lesions. Mol Cell Endocrinol (2009) 0.86
Yes-associated protein 1 is activated and functions as an oncogene in meningiomas. Mol Cancer Res (2012) 0.86
Caveolin-1, caveolae, and glioblastoma. Neuro Oncol (2012) 0.86
Identification of candidates for tumor-specific alternative splicing in the thyroid. Genes Chromosomes Cancer (2006) 0.85
Arginase 2 and nitric oxide synthase: Pathways associated with the pathogenesis of thyroid tumors. Free Radic Biol Med (2010) 0.85
How to minimize complications in thyroid surgery? Auris Nasus Larynx (2009) 0.85
Noninvasive imaging of infection after treatment with tumor-homing bacteria using Chemical Exchange Saturation Transfer (CEST) MRI. Magn Reson Med (2013) 0.84
Proteomic approaches identify members of cofilin pathway involved in oral tumorigenesis. PLoS One (2012) 0.83
Cancer biomarker discovery for cholangiocarcinoma: the high-throughput approaches. J Hepatobiliary Pancreat Sci (2014) 0.83